Scale-Up of Nanopharmaceutical Formulations: Integrating Critical Quality Attributes, Process Analytical Technology, and Regulatory Challenges into a Decision Framework

Nanopharmaceuticals are generally successful at laboratory scale, but once production levels rise, their quality suffers, and the reasons for this are seldom explored in relation to monitoring and regulatory requirements. This critical review considers 90 peer-reviewed sources, 77 of which are published from 2020 onward, and explores the relationship between formulation composition, process conditions, particle attributes, in-process monitoring, and regulatory expectations during scale-up. The size, polydispersity, payload integrity and storage stability of lipid nanoparticles, liposomes, polymeric nanoparticles, nanoemulsions and nanocrystals respond differently to changes in mixing, shear, filtration time and freezing history. Quality-by-design studies rarely report design spaces at production scale and most process analytical technology work is focused on particle size, while encapsulation, payload integrity and lipid quality are still tested offline. Nanomedicines are regulated on a case-by-case basis in regulatory documents and no harmonized comparability pathway exists. An unvalidated framework is presented in the review linking material attributes, process parameters, quality attributes, monitoring tier and comparability evidence through a decision matrix and decision-flow diagram. The framework identifies scale sensitive, history sensitive and material sensitive attributes and assigns a monitoring and control strategy to each of them. The priority research needs are inline methods for payload integrity, scale-transferable design spaces, validated digital models and agreed comparability criteria. The proposals have to be tested in prospective real manufacturing programs.

Authors

Institutions

Publication Details

Journal
TMP Universal Journal of Advances in Pharmaceutical sciences
Published
2026-11-17
DOI
https://doi.org/10.69557/6wqvtk56
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Scale-Up of Nanopharmaceutical Formulations: Integrating Critical Quality Attributes, Process Analytical Technology, and Regulatory Challenges into a Decision Framework

Arbaz Khan
2 links
TMP Universal Journal of Advances in Pharmaceutical sciences
Nanoparticle-Based Drug Delivery
article

Scale-Up of Nanopharmaceutical Formulations: Integrating Critical Quality Attributes, Process Analytical Technology, and Regulatory Challenges into a Decision Framework

Arbaz Khan
article en

Abstract

Nanopharmaceuticals are generally successful at laboratory scale, but once production levels rise, their quality suffers, and the reasons for this are seldom explored in relation to monitoring and regulatory requirements. This critical review considers 90 peer-reviewed sources, 77 of which are published from 2020 onward, and explores the relationship between formulation composition, process conditions, particle attributes, in-process monitoring, and regulatory expectations during scale-up. The size, polydispersity, payload integrity and storage stability of lipid nanoparticles, liposomes, polymeric nanoparticles, nanoemulsions and nanocrystals respond differently to changes in mixing, shear, filtration time and freezing history. Quality-by-design studies rarely report design spaces at production scale and most process analytical technology work is focused on particle size, while encapsulation, payload integrity and lipid quality are still tested offline. Nanomedicines are regulated on a case-by-case basis in regulatory documents and no harmonized comparability pathway exists. An unvalidated framework is presented in the review linking material attributes, process parameters, quality attributes, monitoring tier and comparability evidence through a decision matrix and decision-flow diagram. The framework identifies scale sensitive, history sensitive and material sensitive attributes and assigns a monitoring and control strategy to each of them. The priority research needs are inline methods for payload integrity, scale-transferable design spaces, validated digital models and agreed comparability criteria. The proposals have to be tested in prospective real manufacturing programs.

TMP Universal Journal of Advances in Pharmaceutical sciencesVol. 2(4)
Mansoura University (EG), Al Mansour University College (IQ), Mandsaur University (IN)
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon